Dr James Thaventhiran is a Principal Investigator and Theme Lead at the MRC Toxicology Unit, University of Cambridge, where he investigates how adaptive immune lymphocytes resist anti-proliferative inflammatory signals. He is also a clinical immunologist at Addenbrooke’s Hospital, where his clinical studies on patients with primary and secondary immunodeficiency have the goal of identifying novel immunodeficiencies and therapies.